EU adds kidney disease reduction to Ozempic label, about six weeks before FDA
The Ozempic label now names kidney benefits in both Europe and the US, a change that affects how the drug is formally described for adults who have type 2 diabetes along with chronic kidney disease.
European regulators cleared Novo Nordisk to add a reduction in kidney disease to the Ozempic label on December 12, 2024, about six weeks before US regulators reached the same decision [1]. The US Food and Drug Administration approved Ozempic (semaglutide) on January 28, 2025, as the only GLP-1 receptor agonist that reduces the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1].
Both changes apply to Ozempic, the semaglutide brand. The labeled group is specific: adults who have both type 2 diabetes and chronic kidney disease [1]. The FDA language pairs kidney outcomes with cardiovascular death, so the label covers both worsening kidney disease and death from cardiovascular causes in that group [1].
The evidence behind the kidney language comes from the FLOW trial, which examined the effects of semaglutide in patients with chronic kidney disease and type 2 diabetes and was published in the New England Journal of Medicine in 2024 [1]. The two regulatory decisions were covered together in Kidney News, which published its report on March 7, 2025 [1]. That coverage calls semaglutide a "game-changer drug" for these patients and also flags access challenges, including questions about what the medicine costs [1].
Several details have not been reported. The size of the kidney risk reduction as written into the European or US label is not given in the coverage of the two decisions [1]. Whether the European and American label text is worded the same way has not been reported [1]. No matching label changes for Wegovy or Rybelsus, the other semaglutide products, have been described, and whether any were requested has not been reported [1]. The same is true for tirzepatide, sold as Mounjaro and Zepbound, which is a different molecule.
Why it matters for patients
A label change is not a new medicine, but it changes what a medicine is formally approved to do. For an adult with type 2 diabetes and chronic kidney disease, the Ozempic label now names a kidney benefit, which gives doctors clearer grounds to consider and discuss the drug in that situation [1].
Label language can also shape coverage, because insurers and pharmacy benefit managers often tie prior authorization and formulary rules to approved indications. The reporting on the two decisions raises access as an open issue rather than a settled one [1]. How any individual plan handles a prescription, and what a patient pays, were not described in the account of the label changes [1].
Among the semaglutide brands, the kidney language applies to Ozempic as far as has been reported [1]. People taking Wegovy or Rybelsus should not assume their labels carry the same wording, and people taking tirzepatide products are in a different situation. Patients who want to know how the kidney indication affects their own prescription can ask their prescriber or pharmacist what their plan currently requires.
The kidney indication also does not replace standard kidney care. The reports describe a drug label, not a change to monitoring or other treatment, and no such changes are detailed in the coverage [1].
What happens next
Both label changes are already in effect, following the December 12, 2024 European action and the January 28, 2025 FDA approval [1]. No further regulatory steps for this kidney indication have been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.